Anti-tumor prodrug as well as preparation method and application thereof

Acid-sensitive prodrugs are constructed through neuric acid and gemcitabine, and their rupture executive function in the tumor microenvironment is used to solve the problems of drug delivery and toxic side effects, and efficient treatment and nerve repair of brain gliomas are achieved.

CN119060112APending Publication Date: 2024-12-03DALIAN NATIONALITIES UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411246958.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively pass through the blood-brain barrier to deliver drugs to the glioma site, and the toxic side effects of chemotherapy drugs are difficult to resolve, affecting the treatment effect and patient recovery.

Method used

Neuric acid and chemotherapy drug gemcitabine are used to construct acid-sensitive amphiphilic prodrug compounds. After using the properties of neuric acid, the acid-sensitive bonds break in the tumor microenvironment, and chemotherapy drugs are performed to kill tumor cells and nerves. Acids repair the function of neural tissue.

Benefits of technology

It realizes efficient delivery of drugs in the brain and tumor treatment, while reducing the toxic and side effects of chemotherapy drugs, integrating treatment and rehabilitation, and has good prospects for use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060112A_ABST
    Figure CN119060112A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biochemistry, and particularly relates to an anti-tumor prodrug and a preparation method and application thereof.The anti-tumor prodrug is composed of the tail of nervonic acid and the head of a hydrophilic chemotherapeutic drug, the hydrophilic chemotherapeutic drug is gemcitabine, and the tumor is brain glioma. The acid-sensitive amphiphilic prodrug compound is synthesized based on nutrient substance nervonic acid capable of penetrating a blood brain barrier and a chemotherapeutic drug as raw materials, and after the prodrug compound reaches a tumor site, the prodrug compound is separated into the nervonic acid and the chemotherapeutic drug to respectively execute respective functions due to relatively low pH in a tumor microenvironment and automatic breakage of an acid-sensitive bond, so that the prodrug compound can be applied to tumor treatment. The chemotherapy medicine kills glioma cells, nervonic acid repairs nervous tissues, the toxic and side effects of the chemotherapy medicine are fundamentally solved, and the treatment effect and the rehabilitation effect are integrated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biochemical technology, and specifically relates to an anti-tumor prodrug and a preparation method and application thereof. Background Art

[0002] Gliomas are one of the most common types of primary brain tumors and can cause significant morbidity and mortality. Since most gliomas are characterized by invasive growth and malignant transformation, they have unclear boundaries with surrounding brain tissues, are prone to recurrence, and are very difficult to treat. The annual incidence of gliomas in my country is 5 / 100,000-8 / 100,000, and the 5-year mortality rate is second only to pancreatic cancer and lung cancer among systemic tumors. There are three main methods for treating gliomas: surgical resection, radiotherapy, and chemotherapy. Due to the characteristics of gliomas, chemotherapy is an indispensable treatment method. However, due to the existence of the blood-brain barrier, it is difficult for drugs to be effectively delivered to the lesion site to exert their therapeutic effects. In addition, studies have shown that damage to the blood-brain barrier is associated with many brain diseases, so how to further develop new drugs and new drug delivery systems on the basis of protecting the blood-brain barrier from damage remains a research focus.

[0003] Based on non-invasive means, systemic administration to the brain lesion site, through the endogenous transport mechanism to deliver drugs across the blood-brain barrier, off-target exposure and other causes limited penetration, which is not enough to improve brain diseases. In order to improve the efficiency of crossing the blood-brain barrier, physical or chemical methods (exogenous effects) are used to temporarily induce the disconnection of tight junctions of endothelial cells and open the blood-brain barrier. For example, focused ultrasound combined with microbubbles and arterial injection of hypertonic agent mannitol open the blood-brain barrier. This short-term, local destruction of the blood-brain barrier can promote, increase and improve the entry of drugs into brain tissue. With the continuous development of minimally invasive surgery, a series of techniques can be used to bypass the blood-brain barrier and reach the tumor site through local direct administration. For example, the convection-enhanced delivery method has been used in clinical trials. Clinically, under the guidance of MRI, chemotherapy drugs are directly delivered to the brain tumor area through the implantation of catheters to increase drug accumulation. Laser interstitial thermal therapy is to heat and destroy the tumor by directional implantation of laser optical fiber. Both non-invasive and invasive methods mentioned above inevitably cause complications (cerebral edema, infection, etc.). Therefore, there is an urgent need to explore a new type of drug that can not only effectively treat brain gliomas, but also repair damaged brain tissue. Summary of the invention

[0004] The purpose of the present invention is to provide an anti-tumor prodrug and a preparation method and application thereof. The anti-tumor prodrug is separated into neuraminic acid and chemotherapy drugs in the tumor microenvironment to perform their respective functions. The chemotherapy drugs kill glioma cells, and neuraminic acid repairs nerve tissue, which fundamentally solves the toxic and side effects of chemotherapy drugs, integrates treatment and rehabilitation, and has good prospects for use.

[0005] The objective of the present invention is achieved through the following technical solutions: The present invention provides an anti-tumor prodrug, which consists of the tail of neuraminic acid and the head of a hydrophilic chemotherapy drug.

[0006] Furthermore, the hydrophilic chemotherapy drug is a water-soluble chemotherapy drug such as gemcitabine and hydroxyurea.

[0007] Furthermore, the tumor is a glioma.

[0008] The present invention also provides a method for preparing an anti-tumor prodrug, comprising the following steps: (1) dissolving nervonic acid in a DMF solution containing HATU and DIPEA to react and obtain a reaction solution; (2) adding a DMF solution containing gemcitabine to the reaction solution, stirring and reacting to obtain a mixture solution; (3) The mixture solution is concentrated under reduced pressure and then separated and purified by column chromatography to obtain the anti-tumor prodrug.

[0009] Furthermore, the ratio of gemcitabine to neuraminic acid is 0.5-2:1.

[0010] Furthermore, in step (1), the reaction is carried out in an ice bath for 1-2 hours.

[0011] Furthermore, in step (2), the stirring reaction is carried out at room temperature for 24-36 hours.

[0012] Furthermore, in step (3), the column chromatography separation and purification process uses an eluent of dichloromethane and methanol in a volume ratio of 10 / 1, and 200-300 mesh silica gel as a filling carrier.

[0013] The present invention also provides an application of an anti-tumor prodrug in the preparation of drugs related to the treatment of brain glioma.

[0014] The present invention innovatively uses neuraminic acid and the chemotherapy drug gemcitabine to construct a prodrug. Neuroacid, also known as shark acid, is named after it was first discovered in shark brains. Neuroacid is recognized as the core natural component of brain nerve fibers and nerve cells, and is also the only dual-effect magical substance that can repair and dredge damaged brain nerve fibers and promote the regeneration of nerve cells. Lack of neuraminic acid will cause brain diseases such as sequelae of cerebral stroke, Alzheimer's disease, cerebral palsy, brain atrophy, memory loss, insomnia and forgetfulness. Neuroacid is difficult for the human body to produce on its own and can only be supplemented by in vitro intake. Neuroacid can completely pass through the blood-brain barrier, directly act on nerve fibers to repair and dredge, regenerate damaged and detached protective sheaths, dissolve necrotic tissue that blocks the channels, and induce self-growth and division of nerve fibers.

[0015] Neuroacid has a free carboxyl group, so it can be used to form acid-sensitive ester bonds, hydrazone bonds, imine bonds, etc. with chemotherapy drugs to make amphiphilic prodrug compounds. When neuroacid carries chemotherapy drugs across the blood-brain barrier and into the tumor, the acid-sensitive bonds break due to the acidic microenvironment of the tumor, forming neuroacid and chemotherapy drugs separately and performing their respective functions.

[0016] Combined with gemcitabine, a chemotherapy drug for multiple solid tumors, acylation at the 4-(N)-position of gemcitabine did not impair the efficacy of gemcitabine. Due to the acidic tumor microenvironment, the amide bond between neuraminic acid and gemcitabine is cleaved; after entering the cell, the amide bond can also be hydrolyzed by intracellular amide enzymes such as cathepsin B or cathepsin D, thereby regenerating gemcitabine and neuraminic acid with drug activity. The chemotherapy drug gemcitabine kills tumor cells; neuraminic acid repairs nerve tissue.

[0017] It is known that gemcitabine is rapidly deaminated to the inactive metabolite 2,2-difluorodeoxyuridine in the blood and is rapidly excreted in the urine; in the liver, it is extensively degraded to inactive metabolites by cytidine deaminase. The conjugated polymer of gemcitabine increases the half-life of the drug in plasma by reducing its renal clearance, which depends on the molecular weight of the polymer. Therefore, the conjugation of gemcitabine with neuraminic acid increases the residence time in the blood circulation.

[0018] The beneficial effects of the present invention are: Based on the nutrient neuraminic acid that can penetrate the blood-brain barrier and chemotherapy drugs as raw materials, an acid-sensitive amphiphilic prodrug compound is synthesized. When it reaches the tumor site, the acid-sensitive bond automatically breaks due to the low pH in the tumor microenvironment, and the prodrug compound separates into neuraminic acid and chemotherapy drugs, which perform their respective functions. The chemotherapy drugs kill glioma cells, and neuraminic acid repairs nerve tissue, fundamentally solving the toxic side effects of chemotherapy drugs, and integrating treatment and rehabilitation, with good prospects for use. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0020] Figure 1 The synthetic route of the brain glioma prodrug of the present invention is as follows; Figure 2 This is a mass spectrometry analysis result diagram of neuraminic acid-gemcitabine prodrug compound; Figure 3 is the NMR spectrum of neuraminic acid-gemcitabine prodrug compound; Figure 4 is the infrared spectrum of the neuraminic acid-gemcitabine prodrug compound; Figure 5 It is the acid-sensitive validation diagram of the neuraminic acid-gemcitabine prodrug compound; Figure 6 is the HPLC diagram of neuraminic acid-gemcitabine prodrug compound; Figure 7 is an ion chromatogram of neuraminic acid-gemcitabine prodrug compound; Figure 8 This is the NMR image of the coupling between neuraminic acid and the chemotherapy drug hydroxyurea. DETAILED DESCRIPTION

[0021] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0022] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0023] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0024] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0025] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0026] The brain glioma prodrug of the present invention consists of two parts: the tail of neuraminic acid and the head of the hydrophilic chemotherapy drug.

[0027] Neuroacid (NA) is the main fatty acid found in various sphingolipid species in the central nervous system. It can easily cross the blood-brain barrier and reach the brain tissue, and has important biological functions in medical care for brain development and injury repair. In addition, neuraminic acid also has a modifiable carboxyl group, so it can form an acid-sensitive linker with water-soluble chemotherapeutic drugs to prepare amphiphilic prodrug compounds that can penetrate the blood-brain barrier.

[0028] In the following text, HATU: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; DIPEA: N,N-diisopropylethylamine; DMF: N,N-dimethylformamide; wherein HATU was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; DIPEA was purchased from Tianjin Comeo Chemical Reagent Co., Ltd.; DMF was purchased from Tianjin Comeo Chemical Reagent Co., Ltd.; gemcitabine was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; and neuraminic acid was purchased from Shanghai Ronghe Pharmaceutical Technology Development Co., Ltd.

[0029] Specific preparation method of brain glioma prodrug: Take nervonic acid (1 mmol) and dissolve it in a DMF solution containing HATU and DIPEA (the ratio of nervonic acid to activator (HATU and DIPEA) is controlled at 1:1.2, and the reaction effect is best) and react for 1-2 hours under ice bath conditions. Then add a DMF solution containing gemcitabine (1 mmol). Stir the mixture at room temperature for 24-36 hours. After the reaction is completed, the reaction solution is concentrated under reduced pressure, and column chromatography separation and purification is performed using an eluent of dichloromethane and methanol in a volume ratio of 10 / 1 and 200-300 mesh silica gel as a filling carrier to obtain a nervonic acid-gemcitabine prodrug compound. The specific synthesis route is as follows Figure 1 shown.

[0030] The present invention is specifically described below by way of examples.

[0031] Example 1 The specific preparation method of the brain glioma prodrug in this embodiment 1 comprises the following steps: Take nervonic acid (1 mmol, 366 mg) and dissolve it in 5 mL of DMF solution containing HATU (1.2 mmol, 456 mg) and DIPEA (1.2 mmol, 155 mg) (the best effect is achieved when the condensing agent HATU and DIPEA is 1.2-1.5 times the reactant in the actual reaction process), and react for 2 h under ice bath conditions. Then add DMF (5 mL) solution containing gemcitabine (1 mmol, 263 mg). Stir the mixture at 25 °C for 24 h. After the reaction is completed, the reaction solution is concentrated under reduced pressure, and column chromatography is used to separate and purify the nervonic acid-gemcitabine prodrug compound using an eluent of dichloromethane and methanol in a volume ratio of 10 / 1 and 200-300 mesh silica gel as a filling carrier.

[0032] The mass spectrometry analysis results of the above-mentioned neuraminic acid-gemcitabine prodrug compound are shown in the figure below: Figure 2 As shown by Figure 2 It can be seen that m / z 610.44 is the molecular ion peak of neuraminic acid combined with gemcitabine, proving that the NA-Gem prodrug molecule was synthesized in this example.

[0033] The NMR spectrum of the above-mentioned neuraminic acid-gemcitabine prodrug compound is as follows: Figure 3 As shown by Figure 3 It can be seen that the signal peak at the chemical shift of 10.98ppm is the signal peak of the amide bond hydrogen, 4.15ppm and 3.87ppm are the signal peaks of the hydrogen on the hydroxyl group of gemcitabine; 0.84~1.53ppm belongs to the signal peak of the hydrogen on neuraminic acid.

[0034] The chemical structure of NA-Gem was further characterized by FTIR. Figure 4 As shown by Figure 4 It can be seen that at 1660cm -1 and 1556cm -1 The characteristic signal peak of the amide bond (-CO-NH-) is at the position of the prodrug. This indicates that neuraminic acid has successfully bound to gemcitabine. The prodrug compound was disconnected in a slightly acidic environment, and the acylation of gemcitabine at the 4-(N)-position did not damage the efficacy of gemcitabine. Gemcitabine is a pyrimidine anti-tumor drug, which belongs to the cell cycle-specific antimetabolite class. Its main metabolites are mixed with DNA in cells and mainly act in the G1 / S phase of the cell cycle. The acid-sensitive verification diagram of the neuraminic acid-gemcitabine prodrug compound is shown in the figure below. Figure 5 As shown by Figure 5 It can be seen that when the pH is low, the acid-sensitive bond automatically breaks, and the prodrug compound is separated into neuraminic acid and chemotherapeutic drugs to perform their respective functions, and has good acid sensitivity. In summary, the specific preparation method in Example 1 is used to successfully obtain the neuraminic acid-gemcitabine prodrug compound.

[0035] At the same time, the purity of the prodrug was detected by high performance liquid chromatography, as shown in FIG. Figure 6 As shown, combined with the maximum absorption value of the ultraviolet spectrum of the prodrug, the mobile phase used methanol: water = 90%: 10%, and it was finally found through testing that the purity of the prodrug prepared in this example was 98.66%.

[0036] An in vitro blood-brain barrier model was constructed by Transwell (permeable cell culture chamber). The prodrug compound was dissolved in the cell culture medium and co-cultured (cultured) with endothelial cells in the upper chamber. The fluorine element in the cell culture medium in the lower chamber of Transwell was quantitatively analyzed using an ion chromatograph. The results showed that the fluorine element changed gradually over time, proving that the prodrug compound can pass through the blood-brain barrier. The specific results are as follows Figure 7 As shown, the NMR images of neuraminic acid coupled with the chemotherapy drug hydroxyurea are shown in Figure 8 shown.

[0037] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.

Claims

1. An anti-tumor prodrug, characterized in that: The anti-tumor prodrug consists of a tail of neuraminic acid and a head of a hydrophilic chemotherapeutic drug.

2. The anti-tumor prodrug according to claim 1, characterized in that The hydrophilic chemotherapy drug is gemcitabine.

3. The anti-tumor prodrug according to claim 1, characterized in that The tumor is a brain glioma.

4. The method for preparing an anti-tumor prodrug according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) dissolving nervonic acid in a DMF solution containing HATU and DIPEA to react and obtain a reaction solution; (2) adding a DMF solution containing gemcitabine to the reaction solution, stirring and reacting to obtain a mixture solution; (3) The mixture solution is concentrated under reduced pressure and then separated and purified by column chromatography to obtain the anti-tumor prodrug.

5. The preparation method according to claim 4, characterized in that: The ratio of gemcitabine to neuraminic acid is 0.5-2:

1.

6. The preparation method according to claim 4, characterized in that: In step (1), the reaction is carried out in an ice bath for 1-2 hours.

7. The preparation method according to claim 4, characterized in that: In step (2), the stirring reaction is carried out at room temperature for 24-36 hours.

8. The preparation method according to claim 4, characterized in that: In step (3), the column chromatography separation and purification process uses an eluent of dichloromethane and methanol in a volume ratio of 10 / 1, and 200-300 mesh silica gel as a filling carrier.

9. Use of the anti-tumor prodrug according to any one of claims 1 to 3 in the preparation of drugs for treating brain glioma.